
Work Here?
Vetoquinol develops and distributes animal health medicines and care products worldwide. Its focus is on veterinary pharmaceutical solutions, including antiseptics and other drugs used in treating companion and farm animals, with products marketed through a global network. The company’s products are developed, manufactured, and sold to veterinarians and distributors to address animal health needs; customers access solutions via a direct presence in 24 countries and distribution in about 100 countries. What sets Vetoquinol apart is its long family-led history spanning three generations, its IPO to accelerate international growth, and its sustained global footprint across multiple regions, enabling broad market reach and local presence. The company’s goal is to improve the health and well-being of animals worldwide by expanding access to veterinary medicines and care, strengthening its product portfolio, and growing its geographic footprint.
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Paris, France
Founded
1933
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$0
Below
Industry Average
Funded Over
1 Rounds
Health Insurance
Disability Insurance
Paid Vacation
Commuter Benefits
Wellness Program
Professional Development Budget
Training Programs
Vetoquinol, a French animal health company, reported first-quarter 2026 sales of €125 million, down 4.3% on a reported basis but flat at constant exchange rates. Excluding currency effects and a product line simplification programme, sales increased 1.2% year-on-year. Exchange rate headwinds reached €5.2 million, primarily affecting the United States and India. The product line simplification programme impacted sales by €1.7 million. Essential products sales totalled €83 million, stable at constant exchange rates, whilst complementary products grew, driven by strong US performance. US sales rose 15.6% at constant exchange rates to €28 million. Companion animal products represented 71% of sales at €93 million, whilst farm animal products totalled €38 million. The company described 2026 as a transition year ahead of new product launches in 2027.
Vetoquinol launches Command Centre ACT. The platform creates 'clear accountability' and eases the administrative burden of tracking vaccinations and farm visits. A veterinary pharmaceutical company has launched a dashboard to help ease administrative burdens on farm and mixed practices and drive revenue growth and clinical compliance. Vetoquinol has launched Command Centre ACT, a dashboard extension for its VetImpress data management platform designed for clinical directors and business development staff. The extension is said to draw on practices' data stored within VetImpress or their practice management system to identify revenue opportunities and compliance gaps. Based on analysis using leptospirosis, bovine viral diarrhoea and infectious bovine rhinotracheitis, Vetoquinol estimates that in dairy herds alone, missed vaccination doses, lapsed vaccinations and unvaccinated herds demonstrate an opportunity of around £2,877 annually per farm vet. 'Strategic approach' As well as optimising vaccine scheduling and compliance, Command Centre ACT is said to address regulatory requirements such as Veterinary Medicines Requirements "animals under care" guidelines, automatically flagging farms that are due visits to visually inspect livestock. Vetoquinol product manager Andy Paine said: "The dashboard's name reflects its strategic approach to practice management. "Command Centre ACT enables the user to identify farms requiring attention and assign specific follow-up actions to individual vets through the VetImpress diary and tasks system, creating clear accountability whilst maintaining clinical focus. "We're ultimately selling accountability, but we're striking the right balance between management oversight and clinical autonomy." Work and well being 20 Apr 2026 Small animal 3 Mar 2026
Vetoquinol, a French veterinary pharmaceutical company, reported annual sales of €526 million for 2025, up 0.2% at constant exchange rates but down 2.5% on a reported basis. The company faced historically high negative currency impacts of €14.8 million and a €9.7 million decline from simplifying its Complementary product ranges. Essential Products sales reached €334.5 million, growing 4.1% at constant exchange rates, driven by a strong fourth quarter increase of 8.0%. The company completed transferring manufacturing of its parasiticide range to its own facilities. Essential Products now represent 64% of total sales, up from 61% in 2024. Companion animal products accounted for 72% of sales at €377 million, whilst farm animal products represented 28% at €149 million.
Vetoquinol released the first fluorescent light therapy system for dogs and cats—Phovia—to help accelerate natural skin regeneration.
Mongeau joins Vetoquinol from Nikon Optical, where she most recently served as CEO for Canada and the USA.
Find jobs on Simplify and start your career today
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Paris, France
Founded
1933
Find jobs on Simplify and start your career today